Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Gadolinium Deposition Disease can Result from use of Contrast Agents During MRI & MRA Procedures

February 23, 2018 By Law Offices of Thomas J. Lamb, P.A.


What are Gadolinium-Based Contrast Agents (GBCAs)?

GBCAs are substances that are injected into patients during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images.

Here is a list of GBCAs that are currently approved by the FDA:

  • Ablavar
  • Dotarem
  • Eovist
  • Gadavist
  • Magnevist
  • MultiHance
  • Omniscan
  • OptiMARK
  • ProHance

These substances contain gadolinium, a toxic synthetic heavy metal, which is bonded to a linear or macrocyclic compound in order to reduce toxicity.

While the bonding compounds are designed to help usher gadolinium out of the body, sometimes the bonds break and gadolinium is left behind in the bones, brain, and various tissues within the body.

 

What can happen when Gadolinium remains in the body?

Several conditions can occur as a result of gadolinium retention:

  • Nephrogenic systemic fibrosis (NSF)
  • Gadolinium storage condition
  • Gadolinium deposition disease

NSF occurs in patients with renal insufficiency.  In these patients, gadolinium cannot be removed from the body adequately as a result of decreased kidney function.  As a result, thickening and darkening of the skin, shortening of the muscles and tendons, and other symptoms can occur.  This condition can potentially be fatal.

Gadolinium storage condition is the excess of gadolinium in patients with normal renal function.

Gadolinium deposition disease occurs when a patient has an excess of gadolinium in their system, but they have normal or adequate renal function. Symptoms of this condition can manifest anywhere from a few hours to several weeks after the GBCA injection was administered, and are as follows:

  • Persistent headache
  • Severe pain in the bones, joints, arms, and legs
  • Sensation of sharp pins and needles, cutting, or burning
  • Cognitive impairment
  • Clouded mentation (“brain fog”)
  • Nausea / vomiting
  • Thickening of soft-tissue, tendons, and ligaments
  • Tightness in the hands and feet

 

What actions are being taken?

Regulatory agencies here and abroad have taken steps to warn patients about the potential for gadolinium retention as a result of GBCA use.

In my next article, I will further discuss the specific regulatory actions that have occurred over the years.  I will also discuss the current status of this situation in the U.S. as well as in Europe.

Rest assured that we will continue to monitor the medical literature concerning the risk of NSF and gadolinium deposition disease as a result of GBCA use during MRI and MRA procedures, and report on any significant developments.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 


Gadolinium-Containing Contrast Agents

Free Case Evaluation

Strictly Confidential, No Obligation


 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

 

Filed Under: Unsafe Drugs Tagged With: Ablavar, Dotarem, Eovist, Gadavist, gadolinium, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, GBCAs, Magnevist, mra contrast agents side effects, mri contrast agents side effects, MultiHance, Nephrogenic systemic fibrosis, NSF, Omniscan, OptiMARK, ProHance

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.